Precigen, Inc
PGEN · United States
Share price · PGEN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when PGEN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 5 Nov 2026-16.5%
- 2 Nov 2026-25.9%
Nothing announced by PGEN that day or the session before.
- 29 Oct 2026+9.2%
- 16 Oct 2026-11.3%
Nothing announced by PGEN that day or the session before.
- 5 Oct 2026-9.4%
Nothing announced by PGEN that day or the session before.
- 31 Jul 2026+5.6%
Nothing announced by PGEN that day or the session before.
- 11 Jun 2026+16.5%
- 14 May 2026+10.8%
- 31 Mar 2026+19.1%
- 30 Mar 2026-11.4%
Share of unusual movement by asset
For each asset, the share of PGEN's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(3 total)
| Target & Modality | |||
|---|---|---|---|
Zopapogene imadenovec(Papzimeos) | Approved | HPV6/HPV11 antigens (immunotherapy)Gene therapy / editing | Recurrent Respiratory Papillomatosis |
| Phase 2 | HPV-16/18 E6/E7 antigensGene therapy / editing | Oropharyngeal Cancer HPV-Associated Oropharyngeal Cancer | |
| Phase 1 | CD33Cell therapy | Acute Myeloid Leukemia Relapsed/Refractory Acute Myeloid Leukemia |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (1)
January 2029 (1)
What to watch
Regulatory and conference events
(5)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $74M | $6.6M | $15M+ $31M short-term inv. | —$12M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $55M | $7.3M | $16M+ $22M short-term inv. | —-$18M operating cash flow | report ↗ |
| 2026-Q1 | $23M | $5.6M | $7.5M+ $49M short-term inv. | $7.9M-$44M operating cash flow | report ↗ |
| 2025-Q3 | — | — | $14M+ $107M short-term inv. | $146M-$29M operating cash flow | report ↗ |
| 2025-Q2 | — | — | $14M+ $46M short-term inv. | $27M-$19M operating cash flow | report ↗ |
| 2025-Q1 | $1.3M | $10M | $6.1M+ $74M short-term inv. | $54M-$16M operating cash flow | report ↗ |
| 2024-Q3 | — | — | $25M+ $3.9M short-term inv. | $24M-$23M operating cash flow | report ↗ |
| 2024-Q2 | — | — | $9.6M+ $10M short-term inv. | $59M-$23M operating cash flow | report ↗ |
| 2024-Q1 | — | — | $18M+ $27M short-term inv. | $24M-$14M operating cash flow | report ↗ |
| 2023-Q3 | — | — | $10M+ $64M short-term inv. | $20M-$17M operating cash flow | report ↗ |
| 2023-Q2 | $1.8M | — | $17M+ $72M short-term inv. | $20M-$16M operating cash flow | report ↗ |
| 2023-Q1 | $1.9M | — | $24M+ $94M short-term inv. | $23M-$18M operating cash flow | report ↗ |
| 2022-Q3 | $17M | — | $92M+ $62M short-term inv. | —-$24M operating cash flow | report ↗ |
| 2022-Q2 | $2.9M | — | $50M+ $71M short-term inv. | $18M-$7.0M operating cash flow | report ↗ |
| 2022-Q1 | $32M | — | $41M+ $72M short-term inv. | $19M-$19M operating cash flow | report ↗ |
| 2021-Q3 | $22M | — | $42M+ $73M short-term inv. | $30M-$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $9.7M | $41M | $30M+ $68M short-term inv. | $63M-$88M operating cash flow | report ↗ |
Precigen reported full-year 2025 total revenues of $9.68M, up 146.3% YoY, with PAPZIMEOS contributing $3.4M in net product revenue in the fourth quarter. R&D expense was $41.33M, down 22.1% YoY. Cash and equivalents totaled $30.23M, while cash, cash equivalents, and investments reached $100.4M as of December 31, 2025. The company reported a net loss of $250.64M and a quarterly net burn of $250.64M.
The company transitioned to commercial stage after FDA approval of PAPZIMEOS in August 2025, secured a permanent J-code effective April 1, 2026, and has a Marketing Authorization Application for PAPZIMEOS under EMA review. An open-label redosing study was initiated, and PRGN-2009 Phase 2 trials are ongoing. Management expects current cash plus anticipated PAPZIMEOS sales to fund operations to cash flow break-even by the end of 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $3.9M | $53M | $30M+ $68M short-term inv. | $32M-$68M operating cash flow | report ↗ |
| 2023-FY | $6.2M | $49M | $7.8M+ $55M short-term inv. | $24M-$67M operating cash flow | report ↗ |
| 2022-FY | $27M | — | $49M+ $51M short-term inv. | —-$65M operating cash flow | report ↗ |
| 2021-FY | $104M | — | $43M+ $72M short-term inv. | $23M-$56M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 1 purchase ($25K), 40 sales ($36.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise | 10,744 | $4.72 | $51K | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise | 42,918 | $2.33 | $100K | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise | 2 | $0.96 | $2 | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise | 1 | $1.21 | $1 | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise (derivative) | 10,744 | — | — | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise (derivative) | 42,918 | — | — | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise (derivative) | 2 | — | — | Form 4 |
| 2026-09-23 | Thomasian Harry Jr. · Chief Financial Officer | Option exercise (derivative) | 1 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 205 reporting institutions held 133.6M shares ($511.5M, 37.3% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | Patient Capital Management, LLC | 17,817,387 | $69.0M |
| 2 | BlackRock, Inc. | 15,223,191 | $58.9M |
| 3 | STATE STREET CORP | 10,890,124 | $42.1M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 7,148,996 | $27.7M |
| 5 | Diametric Capital, LP | 6,801,788 | $26.3M |
| 6 | Point72 Asset Management, L.P. | 6,644,361 | $25.7M |
| 7 | TANG CAPITAL MANAGEMENT LLC | 6,417,500 | $24.8M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 4,613,429 | $17.9M |
| 9 | Occam Crest Management LP | 4,269,051 | $16.5M |
| 10 | IRIDIAN ASSET MANAGEMENT LLC/CT | 3,592,730 | $13.9M |
| 11 | Boxer Capital Management, LLC | 3,500,000 | $13.5M |
| 12 | GOLDMAN SACHS GROUP INC | 3,350,477 | $13.0M |
| 13 | CITADEL ADVISORS LLC | 2,702,383 | $10.5M |
| 14 | FRANKLIN RESOURCES INC | 2,633,780 | $10.2M |
| 15 | MORGAN STANLEY | 2,414,322 | $9.3M |